Evidence map›Paper›PMID 39503945›Full record

ReviewAdvances in experimental medicine and biology2025

Flavonoids as Chemosensitizers in Leukemias.

Nigar Huseynova, Melisa Çetinkaya, Züleyha Baran, Rovshan Khalilov, Afat Mammadova, Yusuf Baran

Abstract readReview
PubMed Publisher
In one paragraph

Review in Advances in experimental medicine and biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nigar Huseynova *Department of Biophysics and Biochemistry, Baku State University, Baku, Azerbaijan.
Melisa Çetinkaya *Department of Molecular Biology and Genetics, Laboratory of Cancer Genetics, İzmir Institute of Technology, İzmir, Turkey.
Züleyha BaranDepartment of Pharmacology, Laboratory of Molecular Pharmacology, Anadolu University, Eskişehir, Turkey.
Rovshan KhalilovDepartment of Biophysics and Biochemistry, Baku State University, Baku, Azerbaijan.
Afat MammadovaDepartment of Botany and Plant Physiology, Baku State University, Baku, Azerbaijan.
Yusuf BaranDepartment of Molecular Biology and Genetics, Laboratory of Cancer Genetics, İzmir Institute of Technology, İzmir, Turkey. yusufbaran@iyte.edu.tr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Flavonoids, a diverse group of natural compounds abundant in plants, fruits, and seeds, are not only responsible for the vibrant colors, fragrances, and flavors found in nature but also possess significant health benefits. Representing a secondary metabolite, these phytonutrients contribute to overall well-being. They have garnered considerable interest due to their diverse biological roles, encompassing antioxidant, anti-inflammatory, and anticancer properties. Flavonoids exert anticancer properties by interfering with different signaling pathways and molecules. Also, they have been demonstrated to exert chemosensitization features, where flavonoids may enhance the effectiveness of chemotherapy, and hold promise for improving cancer treatment outcomes as they have been discovered to make cancer cells more responsive to treatment. Understanding their influence on the regulation of cellular signaling provides a foundation for exploring their potential in combination with different chemotherapy agents and their possible single use for cancer treatment. Besides, they are believed to present a cost-effective approach to cancer therapeutics with possible implications for reducing the side effects of the current chemotherapy regimens, which can be a great therapeutic strategy for treating cancer types, including leukemia. This chapter explores potential approaches for creating anticancer treatments, focusing on leukemia, through integrating flavonoid nutraceuticals with traditional chemotherapy agents.

Indexed as

Antineoplastic AgentsAntineoplastic Agents, PhytogenicFlavonoidsLeukemiaAnimalsDrug Resistance, NeoplasmHumansSignal TransductionAntineoplastic AgentsAntineoplastic Agents, PhytogenicFlavonoidsAnticancerChemosensitizationChemotherapeuticsFlavonoidsLeukemia

Identifiers

PMID39503945

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.